Matwings Technology has been named to the Forbes Asia 100 to Watch 2026 list, recognizing the company's achievements in AI-driven protein research and development. Selected from a competitive pool of emerging companies across the Asia-Pacific region, Matwings Technology is one of only 10 companies from mainland China to make this year's list.

Published annually since 2021, the Forbes Asia 100 to Watch list recognizes promising privately held companies across the Asia-Pacific region that demonstrate innovation, growth potential, and industry impact.
With AI-driven innovation as a central theme, the 2026 list selected 100 outstanding companies from nearly 1,000 candidates across 16 countries and territories, spanning 10 emerging sectors, including biotechnology and healthcare, robotics, energy, and green technology.
Matwings Technology's inclusion represents significant international recognition of its technological capabilities, business model, and growth potential.
MatwingsVenus®: An AI-Powered Research Agent
Connecting the Entire Protein R&D Workflow
At the core of Matwings Technology's innovation is MatwingsVenus™, its proprietary AI-powered protein R&D agent.
By integrating an AI-powered biological design platform with an autonomous laboratory, MatwingsVenus™ establishes a closed-loop workflow connecting AI design, automated experimental validation, and iterative optimization, bridging computational research and wet-lab experimentation.
The platform consists of two closely integrated components:
Lightweight AI Biological Design Platform
Powered by tens of billions of protein sequences, more than 200 scientific design tools, and over 50 expert-optimized Skills, the platform enables users to perform research tasks ranging from sequence design and structure prediction to performance analysis through natural-language interactions.
Building on these capabilities, MatwingsVenus™ offers four integrated capability areas: Scientific Tools, Deep Research, Products, and Solutions.
The platform supports scientific research and writing, protein design, and enterprise-level services, including private AI agent deployment and customized Forward Deployed Engineering (FDE) development. These capabilities address diverse needs, from early-stage research exploration to the translation of scientific discoveries into practical applications.
AI-Powered Autonomous Laboratory
Driven by the MatwingsVenus™ platform, the AI-powered autonomous laboratory connects AI design, automated wet-lab validation, and iterative optimization in a continuous, around-the-clock research workflow.
The laboratory incorporates three core automation platforms: plasmid construction and extraction, protein expression, and protein purification.
Together, these systems support automated workflows from gene design to the production of protein samples, substantially improving experimental throughput and data consistency.
The laboratory can support high-throughput workflows and process development across synthetic biology, biopharmaceuticals, enzyme engineering, and related fields.
Industrial Applications:
Expanding the Impact of AI Protein Design
Technological innovation ultimately needs to deliver real-world value. Matwings Technology has already demonstrated the industrial potential of its AI protein design capabilities through multiple projects in innovative drug development and synthetic biology.
GenSci148: AI-Optimized Ophthalmic Biologic
Commissioned by GenSci Pharmaceuticals, Matwings Technology contributed to the molecular engineering, design, and optimization of GenSci148, an innovative ophthalmic biologic.
Following AI-driven optimization, the molecule's binding affinity for VEGF-A increased approximately tenfold, while its triple-blocking activity against VEGF-A, VEGF-C, and VEGF-D improved approximately threefold.
In animal models, the optimized molecule demonstrated sustained inhibitory effects for up to 84 days after administration, alongside improvements in drug developability properties, including thermal stability and expression yield.
Clinical trial applications for all three indications—neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)—have received regulatory approval through China's 30-day review pathway for innovative drugs.
Notably, AI identified beneficial mutation sites located away from the binding interface, demonstrating its potential to expand the molecular design space beyond conventional structure-guided approaches.
First International Partnership for a Biologic Drug Pipeline
In 2025, Matwings Technology entered into a biologic drug pipeline R&D partnership with a leading overseas biotechnology company, marking the company's first international collaboration involving its biologic drug development pipeline.
This milestone reflects growing international recognition of China's AI protein design capabilities and represents an important step toward participation in the global innovative drug development ecosystem.
Expanding Beyond Biopharmaceuticals
Beyond biopharmaceutical development, Matwings Technology has also achieved industrial applications of its AI protein design platform in synthetic biology, industrial enzymes, green manufacturing, and health-related industries.
By extending its integrated computational and experimental protein R&D capabilities beyond drug development into a broader range of industrial applications, Matwings Technology continues to demonstrate the versatility and cross-industry value of its technology platform.